Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase IV Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Sponsor: Pharmazz, Inc.
Listed as NCT05955326, this PHASE4 trial focuses on Acute Cerebral Ischemia and remains actively recruiting participants. Sponsored by Pharmazz, Inc., it has been updated 9 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE4
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE4
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE4
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
▶ Show 4 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — May 2024 [monthly]
Not Yet Recruiting PHASE4
-
Oct 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE4
Status: Recruiting → Not Yet Recruiting
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pharmazz, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .